Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat extension in pediatric heart failure
NCT06428383Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF), sponsored by Merck & Co. Primary endpoints: Participants with adverse events up to 8 years and Participants who discontinued study drug due to an AE up to 8 years. Started Jul 2024; status: active, not recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06428383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428383.